It has been reported that pain occurs in 30% of patients with early cancer, 60 to 70% of patients with advanced cancer, and 75% or more of those with terminal cancer. 1) Pain is one of the most prevalent conditions that diminish the quality of life. A three-step pain elimination ladder has been established by the World Health Organization as a worldwide standard therapeutic program for cancer pain, but there is still pain that remains beyond control with opioids and nonsteroidal antiinflammatory drugs. Therefore, to achieve a breakthrough in combating cancer pain, energetic efforts have been made to develop novel analgesics with fewer adverse effects and new mechanisms of action.
Pharmacological Evaluation of Analgesic Effects of the
Formalin-Induced Pain Model Formalin-induced pain model in mice was carried out according to the method of Tjolsen et al. 9) The ICR mice were acclimated to the acryl cages for 30 min before the formalin injection. Formalin (20 ml of 5% (v/v) formalin solution in saline) was injected subcutaneously into the planter region of the right hind paw (intraplanter injection). Nociceptive response was quantified by the measuring the time spent in licking and biting the injected paw every 5 min with a stopwatch. The responses to formalin showed two phases; early (phase 1) and late (phase 2) phases of responses were recorded 0-5 and 10-40 min after formalin injection, respectively. The total time spent engaging in these responses was calculated in each phase. Z-360, YF476 or devazepide was administered orally 30 min prior to formalin injection. Morphine was administered subcutaneously 15 min prior to formalin injection.
Cancer Pain Model A mouse model of cancer pain was made according to the method of Sasamura et al. 10) B16/BL6 cells (Cell Resource Center for Biomedical Research, Tohoku University), melanoma cells derived from C57BL/6 mouse, were cultured in RPMI1640 medium containing 10% fetal bovine serum at 37°C and a humidified atmosphere of 5% CO 2 . The cells (2ϫ10 5 cells/20 ml) were injected into the planter region of the right hind paw of C57BL/6 mice. The paw withdrawal thresholds in response to probing with calibrated von Frey filaments were determined in the manner described by Chaplan et al.
11) The B16/BL6 transplanted mice were individually placed in suspended cages with wire mesh bottoms and allowed to acclimate to their environment for at least 30 min. The hind paw was stimulated with a series of von Frey filaments applied to the planter surface. Stimulation was initiated with the 0.4 g filament and the 50% paw withdrawal threshold was determined by the non-parametric method of Dixon.
12) Z-360 was administered orally once a day from day 7 after transplantation and paw withdrawal threshold was measured 2 h after administration on day 7, 14 and 21. Regarding the combination test of Z-360 and morphine, animals were given single injections of these drugs on day 14 after transplantation; Z-360 was administered orally 60 min prior to the von Frey test and morphine was administered subcutaneously 15 min before. Devazepide was administered orally once a day from day 7 after transplantation and paw withdrawal threshold was measured 2 h after administration on day 14.
Sulfated Cholecystokinin-8 Induced Emptying of the Gallbladder Emptying of the gallbladder was induced by an intraperitoneal injection of sulfated cholecystokinin-8 (100 ng/kg) into fasted male ICR mice 15 min before the gallbladder isolation. 13 
RESULTS

Effects of Z-360 in Formalin-Induced Pain Model
Oral administration of Z-360 showed 5.0, 23.2 and 37.5% inhibition of the phase 2 responses at doses of 30, 100 and 300 mg/kg, respectively, with significant effect at 300 mg/kg ( the phase 1 responses. Z-360 (300 mg/kg) and morphine (2 mg/kg) administered alone inhibited the phase 2 responses by 47.3% and 46.0%, respectively, and the inhibition rate increased to 71.9% when both drugs were administered together (Fig. 1B , non-parametric Tukey's test).
Effects of CCK Receptor Antagonists in FormalinInduced Pain Model There was a tendency toward a reduction in phase 2 response to formalin after administration of YF476 at an oral dose of 1 mg/kg, but the higher dose of 10 mg/kg did not affect the phase 2 response (Fig. 2A , parametric Dunnett's test). Oral administration of devazepide (0.1-10 mg/kg) showed a marked inhibition of phase 2 response, with significant effects at doses of 1 and 10 mg/kg (Fig. 2B , parametric Dunnett's test). The phase 1 responses were not affected by YF476 and devazepide at doses tested (Fig. 2) .
Effects of Z-360 on the Mechanical Allodynia in Cancer Pain Model Transplantation of B16/BL6 caused allodynia, a significant and marked decrease in pain threshold for mechanical stimulation, in the region around the tumor mass from day 4 to at least day 21 after transplantation. Z-360 was administered orally once a day from day 7 after transplantation and paw withdrawal threshold was measured 2 h after administration on day 7, 14 and 21. On day 7, single administration of doses of 100 and 300 mg/kg produced slight but significant inhibition of allodynia (Fig. 3A , non-parametric Dunnett's test). Anti-allodynic effect was further enhanced by repeated administration of a dose of 100 mg/kg on day 14 and 21 ( Fig. 3A , non-parametric Dunnett's test). The combination effect of single injections of Z-360 and morphine was examined on day 14 after transplantation. Although neither morphine (2.5 mg/kg) nor Z-360 (100 mg/kg) alone exhibited a significant anti-allodynic effect, a combination of these drugs showed significant anti-allodynic effect (Fig. 3B , nonparametric Tukey's test).
The Effect of Devazepide in Cancer Pain Model In these series of experiments, repeated oral administration of Z-360 (100 mg/kg) produced a significant inhibition of cancer-induced allodynia again (Fig. 4 , non-parametric Dunnett's test). Repeated oral administration of devazepide (1, 10 mg/kg) showed a dose-dependent anti-allodynic effect, 246 Vol. 33, No. 2 
Fig. 4. Effects of Devazepide on Cancer Pain in Mice
B16/BL6 cell transplantation and the determination of paw withdrawal threshold were performed as described in Fig. 3 legend. Z-360 and devazepide were administered orally once a day from day 7 after transplantation and the withdrawal threshold was measured 2 h after administration on day 14. Values are represented as the meanϮstan-dard error (nϭ10-12). Data are analyzed using non-parametric Dunnett's test (vs. vehicle, # pϽ0.05).
with significant effect at 10 mg/kg (Fig. 4 , non-parametric Dunnett's test).
The Effect of Z-360 on Sulfated Cholecystokinin-8 Induced Emptying of the Gallbladder An intraperitoneal injection of cholecystokinin-8 induced marked emptying of the gallbladder in fasted mice. It was dose-dependently reversed by oral administration of Z-360 (10-100 mg/kg), with significant effect at a dose of 100 mg/kg (Fig. 5, 
DISCUSSION
Rodent model of formalin-induced pain is frequently used to evaluate behavioral response to noxious stimulation because it closely resembles human responses to painful stimuli. 16, 17) The nociceptive response to formalin shows two phases. The early phase (phase 1) seems to be caused predominantly by C-fiber activation due to the peripheral stimulus, while the late phase (phase 2) appears to be dependent on the combination of an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord. 9) In the present study, we found that single administration of Z-360 (30-300 mg/kg) showed dose-dependent inhibitory effects on the phase 2 response, without effects on the phase 1 response. Thus, the results raise the possibility that the inhibitory effect of Z-360 is due to the modulation of peripheral and/or spinal processes of inflammatory pain but not due to the direct inhibition of nociceptive primary afferents. Z-360 has potent CCK 2 receptor antagonist activity. 5, 6, 18) To determine the role of CCK 2 receptor blockade in the antinociceptive effect of Z-360, we evaluated whether another CCK 2 receptor antagonist YF476 would suppress phase 2 of formalin-induced nociceptive responses. YF476 has been shown to inhibit pentagastrin-stimulated gastric acid secretion, a CCK 2 receptor-mediated process, in dogs in dose-dependent manner with ED 50 value of 0.02 mmol/kg (0.05 mg/kg). 19) Furthermore, YF476 showed the approximate 80% inhibition on pentagastrin-stimulated gastric acid secretion in rats at an intraduodenal dose of 1 mg/kg (unpublished observation, Yoshinaga et al.) . With these findings taken into account, the results that YF476 did not produce a significant inhibition of phase 2 of formalin-induced pain at oral doses of 1 and 10 mg/kg argue against the involvement of CCK 2 receptor in the antinociception. Z-360 almost completely inhibits pentagastrin-stimulated gastric acid secretion in rats at an intraduodenal dose of 3 mg/kg. 18) In this study, Z-360 at an oral dose of 30 mg/kg did not inhibit phase 2 of formalin-induced pain. Thus, these results suggest that the antinociceptive effect of Z-360 is not primarily mediated by the blockade of CCK 2 receptor.
In vitro experiments revealed that Z-360 has affinity for both recombinant human CCK 2 and CCK 1 receptors with K i of 0.47 and 316 nM, respectively. 6) Plasma concentrations of Z-360 are much higher than the K i value for CCK 1 receptor; 1400-4000 nM are the concentrations 0.25-2 h after oral dose of 100 mg/kg. 6) Z-360 has no binding affinity (concentration that required 50% influence at Ͼ10 Ϫ6 M) for other nociception-and antinociception-related receptors, channels and enzymes. From these findings, we speculated that CCK 1 receptor antagonistic activity of Z-360 would be involved in the antinociceptive action, though affinity for the CCK 1 receptor is low. Z-360 exerted a dose-dependent inhibitory effect on cholecystokinin-8 induced gallbladder emptying, a CCK 1 receptor-mediated effect, at doses of 10-100 mg/kg, with a significant inhibition at 100 mg/kg. Devazepide, a CCK 1 receptor antagonist, showed the inhibition as well as Z-360 in this gallbladder emptying model. These results suggest that CCK 1 receptor blockade is conducive to the pharmacological action of Z-360 at oral doses of 100 mg/kg and over. Devazepide showed antinociceptive effects on formalininduced pain after oral doses of 1 mg/kg and over, results suggesting that CCK 1 receptor blockade leads to the inhibition of formalin-induced pain. These results suggest that the antinociceptive effect of Z-360 is mediated via antagonistic action on CCK 1 receptor, rather than CCK 2 receptor.
To evaluate the effects of drugs for cancer pain and to develop more appropriate therapeutic modalities, it is important to use animal models of cancer pain produced by transplanting tumors. 10, [20] [21] [22] [23] [24] Therefore, the analgesic effect of Z-360 was evaluated using a mouse model of cancer pain produced by orthotopic transplantation of B16/BL6 melanoma cells. It was found that Z-360 showed anti-allodynic effect at doses of 100 mg/kg and over. The CCK 1 receptor antagonist devazepide (10 mg/kg) also had anti-allodynic effect in this model, suggesting that the suppressive effects of Z-360 (and also devazepide) are mediated at least by the blockade of CCK 1 receptor.
In this study, the influx rate of Z-360 was determined by the intracarotid artery injection technique and was an extremely low BUI value similar to that of sucrose used as a vascular space marker (Table 1) . 15) Taken together these results indicated that the analgesic effects of Z-360 are mediated by CCK 1 receptor antagonistic action and may not be involved in central nerve system. Several studies reported that CCK 2 receptor antagonists, L-365,260 and CI-988, which can penetrate into the brain, showed the potentiation of morphine analgesia. [25] [26] [27] [28] Z-360 hardly penetrate into the brain and analgesic effects of Z-360 may be due to the blockade of CCK 1 , rather than CCK 2 , receptors. Therefore, the mechanism of the potentiation of morphine analgesia by Z-360 may differ from other CCK 2 receptor antagonists such as L-365,260 or CI-988.
The B16/BL6 cancer pain model is considered to be resistant to existing analgesics. Pain-related responses of this model are inhibited by relatively high doses of morphine, gabapentin and ET A endothelin receptor antagonist, 10, 21, 29) but not respond to by nonsteroidal antiinflammatory drugs such as diclofenac or to other drugs used clinically, such as mexiletine, clonidine, suramin, and baclofen. 21) The notable feature of this cancer pain model is the intensity of mechanical allodynia. Allodynia was much higher in this cancer model than in the neuropathic model by herpes simplex virus type-1 infection in mice. 22) Since mechanical allodynia exerts a profound influence on the quality of life of cancer patients, it may be a good index for the screening of cancer-pain killers.
In clinical study, Z-360 at oral doses of 120 mg and 240 mg showed safety and well-tolerated profiles, and pain relief action in patients with pancreatic cancer. 7) When Z-360 orally administered at a dose of 120 mg to human, the maximum plasma concentration of Z-360 was approximately 3000 nM. This plasma concentration of Z-360 was similar to that at oral administration of Z-360 at a dose of 100 mg/kg to mice. 6) These results suggest that Z-360 exert CCK 1 receptor antagonistic action in human. Therefore, analgesic effects of Z-360 at doses of 100 mg/kg and 300 mg/kg in these mice pain model are considered to associate with the effectiveness of Z-360 for cancer pain relief in patients with pancreatic cancer.
In conclusion, this study suggests that Z-360 has the analgesic effects on inflammatory and cancer pain and that the effect is mediated by blockade of CCK 1 receptor. Z-360 is expected to become a useful drug for the treatment of pancreatic cancer with analgesic effects as well as the prolongation of survival.
